Congenital portosystemic shunt (CPSS) is persistence of an anomalous embryological connection of the portal vein with a large vein of the vena cava system. Clinical presentations include neonatal cholestasis, liver tumors, and encephalopathy, but can be variable in timing and symptomatology. We report 2 girls who presented 10 years apart with the same complaint of early pubarche at age 7 years, with inappropriately low DHEAS levels. In addition to hyperandrogenemia (elevated testosterone and androstenedione) and advanced bone age, both had hyperinsulinemia, and hypothyroxinemia. The 2nd case also had symptomatic hypoglycemia. Presentation of CPSS with this combination of findings in prepubertal children has not been reported previously. With further investigations, we proposed novel mechanisms explaining these manifestations. Hyperandrogenemia is caused by decreased hepatic sulfation of DHEA to less active DHEAS due to shunting of DHEA to systemic circulation. Elevated DHEA is then used for synthesis of more potent androgens. Shunting of postabsorbtive glucose from portal to systemic circulation causes early hyperglycemia leading to exaggerated insulin secretion. Insulin bypasses the hepatic metabolism directly entering into the systemic circulation, which results in hyperinsulinemia, then in turn causes late hypoglycemia. Finally, hypothyroxinemia was linked to thyroxin-binding globulin deficiency, which has not been reported in CPSS.

Keywords:
Premature pubarche, Hyperinsulinemia, Hypothyroxinemia, Congenital portosystemic shunt, Abernethy malformation
1.
Bernard O, Franchi-Abella S, Branchereau S, Pariente D, Gauthier F, Jacquemin E: Congenital portosystemic shunts in children: recognition, evaluation and management. Semin Liver Dis 2012;32:273-287.
2.
Delle Chiaie L, Neuberger P, Von Kalle T: Congenital intrahepatic portosystemic shunt: prenatal diagnosis and possible influence on fetal growth. Ultrasound Obstet Gynecol 2008;32:233-235.
3.
Gitzelmann R, Forster I, Willi UV: Hypergalactosaemia in a newborn: self-limiting intrahepatic portosystemic venous shunt. Eur J Pediatr 1997;156:719-722.
4.
Sakura N, Mizoguchi N, Eguchi T, Ono H, Mawatari H, Naitou K, Ito K: Elevated plasma bile acids in hypergalactosaemic neonates: a diagnostic clue to portosystemic shunts. Eur J Pediatr 1997;156:716-718.
5.
Crespin J, Nemcek A, Rehkemper G, Blei AT: Intrahepatic portal-hepatic venous anastomosis: a portal-systemic shunt with neurological repercussions. Am J Gastroenterol 2000;95:1568-1571.
6.
Ratnasamy C, Kurbegov A, Swaminathan S: Cardiac anomalies in the setting of the Abernethy malformation of the portal vein. Cardiol Young 2007;17:212-214.
7.
Hoeper MM, Krowka MJ, Strassburg CP: Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-1468.
8.
Degos B, Daelman L, Huberfeld G, Meppiel E, Rabier D, Galanaud D, Magis AS, Lyon-Caen O, Samuel D, Sedel F: Portosystemic shunts: an underdiagnosed but treatable cause of neurological and psychiatric disorders. J Neurol Sci 2012;321:58-64.
9.
Lisovsky M, Konstas AA, Misdraji J: Congenital extrahepatic portosystemic shunts (Abernethy malformation): a histopathologic evaluation. Am J Surg Pathol 2011;35:1381-1390.
10.
Kim MJ, Ko JS, Seo JK, Yang HR, Chang JY, Kim GB, Cheon JE: Clinical features of congenital portosystemic shunt in children. Eur J Pediatr 2012;171:395-400.
11.
Duprey J, Gouin B, Benazet MF, Le Gal J: Glucose intolerance and post-stimulatory hypoglycemia secondary to a probably congenital intrahepatic portacaval anastomosis (in French). Ann Med Intern 1985;136:655-658.
12.
Satoh M, Yokoya S, Hachiya Y, Fujisawa T, HoshinoK, Saji T: Two hyperandrogenic adolescent girls with congenital portosystemic shunt. Eur J Pediatr 2001;160:307-311.
13.
Sokollik C, Bandsma RH, Gana JC, van den Heuvel M, Ling SC: Congenital portosystemic shunt: characterization of a multisystem disease. J Pediatr Gastroenterol Nutr 2013;56:675-681.
14.
Alonso-Gamarra E, Parrón M, Pérez A, Prieto C, Hierro L, López-Santamaría M: Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics 2011;31:707-722.
15.
Konstas AA, Digumarthy SR, Avery LL, Wallace KL, Lisovsky M, Misdraji J, Hahn PF: Congenital portosystemic shunts: imaging findings and clinical presentations in 11 patients. Eur J Radiol 2011;80:175-181.
16.
Strott CA: Sulfonation and molecular action. Endocr Rev 2002;23:703-732.
17.
Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, Smeitink JA, Smeets R, Sweep FC, Claahsen-van der Grinten HL, Arlt W: Inactivating PAPSS2 mutations in a patient with premature pubarche. N Eng J Med 2009;360:2310-2318.
18.
Stockigt JR: Free thyroid hormone measurement. A critical appraisal. Endocrinol Metab Clin North Am 2001;30:265-289.
19.
Ain KB, Mori Y, Refetoff S: Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987;65:689-696.
20.
Tahboub R, Arafah BM: Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:769-780.
21.
Liddle RA: Gastrointestinal hormones and neurotransmitters; in Feldman M, Friedman LS, Brandt LJ (eds): Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Amsterdam, Elsevier Health Sciences, 2010, pp 3-25.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.